Alivus Life Sciences Ltd Q1 FY2026 Concall Summary & Transcript Notes

Source transcript PDF: https://www.stockscans.in/document/2udkgsxftkiw34ctoszyvyf3.pdf

# 1. Financial Performance

## A. Key Figures
   * **Revenue:** **₹602 Cr** Q1 FY'26 (+2.2% YoY) · **₹602 Cr** operations (+2.2% YoY)
   * Gross Margin: 55.1% (+400 bps YoY) · Gross Profit: ₹332 Cr (+10.2% YoY)
   * EBITDA Margin: 30.1% (+210 bps YoY) · EBITDA Growth: +9.9% YoY

## B. Revenue Growth
   *   **Divergent Business Trends:** Non-GPL business delivered strong double-digit volume growth, driven by new product launches and favorable market dynamics, offsetting sharp declines in GPL-related revenues.
   *   **Geographic Diversification:** Revenue expansion supported by broad-based growth across India, Europe, emerging markets, LatAm, and Japan, indicating resilient global demand.
   *   **Product Portfolio Resilience:** Top five API products represent only ~35% of sales, underscoring a well-diversified revenue base with limited single-product risk.

## C. Gross Margin
   *   **Margin Recovery Underway:** Gross margin expanded significantly year-on-year, driven by lower raw material costs, operational efficiency gains, and high-margin product mix.
   *   **Sustainable API Margins:** Despite the lapse of PLI benefits, management expects API margins to stabilize in the **28–30% range**, supported by second-gen processes and energy efficiency improvements.

## D. EBITDA Profitability
   *   **EBITDA Outperformance:** EBITDA grew at a faster pace than revenue, reflecting operating leverage and margin expansion, despite elevated opex.
   *   **Opex Normalization:** Operating expenses rose ~14%, but management clarified this reflects normal growth investments with no exceptional items, consistent with prior-quarter trends.

## E. Cash Flow & Capex
   *   **Strategic Investment Phase:** Decline in FATR attributed to deliberate increase in capital investment for future growth, marking a shift from historically low spend during Glenmark ownership.

---

# 2. Product & Pipeline Performance

## A. Key Figures
   *   **HP API Pipeline:** **26** molecules in development (**12** with firm customer interest)
   *   **Total Molecule Pipeline:** **165** high-quality molecules in Alivus pipeline
   *   **DMF/CEP Filings:** **569** global filings as of June 30
   * Iron Complex Pipeline: 1 under FDA review, 1 about to be filed, 2 under active consideration
   *   **Oncology Pipeline:** **14** additional products in development with strong interest

## B. HP API Pipeline
   *   **Commercial Momentum:** HP API pipeline progressing on track, with **12 molecules** triggering plant validation due to firm customer interest, signaling strong commercial traction.
   *   **Growth Foundation:** Non-CDMO API business poised for double-digit growth, supported by deep pipeline breadth, geographic diversification, and recent successful launches.
   *   **Strategic Expansion:** Pipeline leverage extends beyond APIs into potential **CDMO services**, enhancing long-term value capture.

## C. Oncology Projects
   *   **Late-Stage Progress:** Two high-potent oncology APIs in advanced development with strong customer interest, underpinned by favorable characteristics that enhance **bioequivalence potential**—a critical U.S. FDA milestone.
   *   **Commercial Timeline:** Onco pipeline commercialization expected from **late FY '27**, driven by early-market patent expiries, with broad geographic demand signals.

## D. Iron Complex Molecules
   *   **Near-Term Catalyst:** One iron complex API under FDA review, with potential approval within **6 months**, though timing remains subject to additional characterization requests.
   *   **Pipeline Buildout:** Additional filings imminent, with **three molecules** in late-stage pipeline formation, positioning iron complexes as a growing segment.

## E. DMF/CEP Filings
   *   **Global Regulatory Footprint:** Extensive portfolio of **569 active DMF/CEP filings** supports global market access, with **9 HP APIs validated** and **3 in advanced development** targeting a **$61 billion TAM**.

---

# 3. CDMO & Segment Mix

## A. Key Figures
   * CDMO Run Rate: ₹40 Cr avg. over 3 quarters · ₹50 Cr per quarter a very strong possibility post-commercialization
   *   **CDMO Business Mix:** **6–7%** of total business · **12–15%** expected in 4–5 years
   *   **GPL Contract Duration:** **5-year** obligation · **4 years remaining**

## B. Project Run Rate & Outlook
   *   **H2 Commercialization Catalyst:** CDMO ramp-up expected in H2 with fifth project launch, driving run rate toward **₹50 Cr/quarter** on strong project momentum.
   *   **Pipeline Depth Signals Scale:** Five commercial projects underway and two in active discussion, supporting **long-term credibility** in CDMO space.
   *   **Demand Dynamics:** Revenue timing influenced by customer production schedules; delays in two projects due to extended indication development, not demand weakness.

## C. Specialty vs Life Cycle Strategy
   *   **Strategic Balance:** Portfolio mix favors **life cycle management** for stable revenue, while **specialty projects** offer higher-margin, exclusive opportunities.
   *   **Margin Protection:** Both segments benefit from **long-term contracts with price escalation clauses**, insulating margins from annual pricing pressure.
   *   **Execution Focus:** Life cycle projects require regulatory alignment and physical mimicry of innovator APIs; specialty projects emphasize **customization**.

## D. Glenmark vs Non-Glenmark Dynamics
   *   **Lumpy but Secured GPL Demand:** Glenmark segment shows volatility due to supply patterns, but remains underpinned by **5-year contractual obligation** and global API supply role.
   *   **Diversification Momentum:** Non-Glenmark markets gaining traction post-seeding phase, supporting sustainable growth beyond legacy dependencies.

## E. Customer Interest & Engagement Timing
   *   **Dual Partnership Models:** Innovators engage either pre- or post-patent expiry—e.g., **Japanese innovator in Project 5** joined post-expiry—highlighting flexibility in CDMO value proposition.

---

# 4. Manufacturing & Capacity

## A. Key Figures
   *   **Capex:** **₹600 Cr** expected for the year (includes ₹190 Cr overflow)
   *   **Brownfield Expansion:** **260 KL** in Ankleshwar and Dahej

## B. Facility Expansion
   *   **Capex Discipline:** Full-year capex remains on track with prior guidance, funding R&D, Solapur completion, and two major brownfield expansions.
   *   **Strategic Capacity Growth:** ~40% capacity increase driven by Solapur and brownfield projects, with Dahej expansion focused on **CDMO demand** and Ankleshwar supporting **new molecule launches**.
   *   **Commercial Readiness:** Dahej brownfield project will enable **immediate commercial supply** post-completion due to existing operational status and tight utilization.
   *   **Long-Term Planning:** Current capacity provides **2-year runway**; exploration of a

   **C. S. FDA-approved site at Dahej scale** continues for strategic resilience.

## C. Solapur Ramp-up
   *   **Operations On Track:** Solapur facility scheduled to begin operations in **Q4**, with commercial production and ROW business targeted in **first half of next year**.
   *   **Phased Revenue Impact:** Initial contribution from Solapur will be **bottom-line accretive** via backward integration and flow chemistry, with top-line growth expected to build over time.

## D. FDA Inspections
   *   **Regulatory Milestone Achieved:** Both Dahej (May 26–30) and Ankleshwar (late January) received **NAI-class EIRs** from the U.S. FDA, marking first inspections in nearly **6 years** and affirming compliance at key facilities.

---

# 5. Technology & Innovation

## A. Key Figures
   *   **R&D Expenditure:** ₹65 Cr FY23 · ₹80 Cr FY25 · ₹21 Cr Q1 FY26

## B. Chemistry Platform
   *   **Strategic Focus Confirmed:** Company to remain exclusively on chemistry platform, ruling out biologics due to inefficiency and sustainability concerns.
   *   **Flow Chemistry Advantage:** Prioritizing flow chemistry for its **investment-light** profile, faster payback, and **reusable platform** potential; one project already commercial with **substantial cost reductions**.

## C. Backward Integration & Growth Strategy
   *   **Next-Gen Process Development:** Strategic shift toward backward integration and CIP to build proprietary, cost-efficient processes for generics pipeline.
   *   **Inorganic Growth Active:** Acquisitions are **"definitely on the table"**, with focus on **capability enhancement** rather than capacity, supported by strong balance sheet.

---

# 6. Risks & Regulatory Execution

## A. CDMO Delivery Risk
   *   **Headline:** Regulatory execution in life cycle projects and delivery of tailored solutions in specialty projects remain key challenges for the CDMO business.

---

# 7. Guidance & Outlook

## A. Key Figures
   *   **Volume Growth Guidance:** **Mid-teens** FY '26 · **At least high-single-digit** FY '27–'28
   *   **Revenue Growth Guidance:** **High single digits** FY '26 (pricing pressure) · **Upside potential** as pipeline matures
   *   **Margin Guidance:** **28%–30%** band maintained

## B. Volume Growth
   *   **H2 Rebound Expected:** FY '26 volume growth on track for mid-teens, with **stronger H2 performance** anticipated due to GPL recovery and CDMO ramp-up.
   *   **Sustained Momentum:** Multi-year growth outlook remains solid, supported by **maturing pipeline projects** and **oncology commercialization** from H2 FY '27.

## C. Margin Forecast
   *   **Stable Margin Trajectory:** Margins guided to remain in the **28%–30% range**, reflecting disciplined cost management despite strategic investments.

## D. Long-Term Profit Target
   *   **Ambitious Profit Roadmap:** Management sees a path to **doubling net profits over five years**, with potential to approach **₹1,000 Cr net profit**, though not formal guidance.
   *   **Strategic Investment Focus:** CDMO expansion requires incremental capacity and investment, while generics remain **stable with controlled R&D needs**.